ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 287

Interleukin-35 in Idiopathic Inflammatory Myopathies

Herman F. Mann1, Hana Hulejova2,3, Josef Zámecník4, Jaromir Hacek5, Mária Filková6, Olga Kryštufková7, J Vencovsky8 and Ladislav Senolt9, 1Department of Experimental Rheumatology, Institute of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, 31st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 4Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, 5Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8Institute of Rheumatology, Charles University, Prague, Czech Republic, 9Institute of Rheumatology, Prague, Czech Republic

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cytokines and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-35 (IL-35) is a newly described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. IL-35 exerts immunomodulatory activities in several human autoimmune inflammatory diseases. Our objective was to assess IL-35 expression in muscle tissue and serum levels of IL-35   in myositis patients compared to healthy controls and characterise its potential association with myositis disease activity. 

Methods: The expression of IL-35 was studied by primary rabbit anti-human EBI3 polyclonal antibody and mouse anti-human p35 monoclonal antibody in a series of 19 muscle biopsy samples of idiopathic inflammatory myopathies (9 dermatomyositis/DM, 10 polymyositis/PM) and 10 cases of non-inflammatory myopathies and 10 control muscles biopsies. Serum levels of IL-35 were determined in 28 DM, 26 PM and 17 cancer associated myositis patients as well as in 40 healthy controls. Disease activity was evaluated by the score of the Myositis Disease Activity Assessment Tool (MYOACT), including both extramuscular, muscular and the physician’s score of overall disease activity. 

Results: Both IL-35 subunits were found in immune cells of the inflammatory infiltrates in idiopathic inflammatory myopathies, but not in muscle cells. No immunoreactivity was observed in muscle tissue of healthy controls and in non-inflammatory myopathies. IL-35 serum levels were increased in all myositis patients compared to healthy controls (p< 0.001). There were no differences in IL-35 serum levels among myositis subgroups. In patients with PM, but not DM, serum IL-35 levels correlated with MYOACT score (r=0.548, p=0.023), lactate dehydrogenase (r=0.621, p=0.024), CRP (r=0.632, p=0.009) and physician’s score (r=0.514, p=0.042). 

Conclusion:

IL-35 subunits are overexpressed in inflamed muscle tissue and elevated circulating IL-35 levels are associated with several disease activity parameters in polymyositis patients. These data suggest potential role of IL-35 in the pathogenesis of inflammatory myopathies.

Acknowledgement: Supported by MHCR support for conceptual development of a research organization (023728) and BTCure (115142-2).


Disclosure: H. F. Mann, None; H. Hulejova, None; J. Zámecník, None; J. Hacek, None; M. Filková, None; O. Kryštufková, None; J. Vencovsky, MedImmune Ltd, 5; L. Senolt, None.

To cite this abstract in AMA style:

Mann HF, Hulejova H, Zámecník J, Hacek J, Filková M, Kryštufková O, Vencovsky J, Senolt L. Interleukin-35 in Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/interleukin-35-in-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-35-in-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology